Roche to Present Ocrevus Data Showing Delayed Wheelchair Need in MS Patients

Date : 06/14/2018 @ 1:56AM
Source : Dow Jones News

Roche to Present Ocrevus Data Showing Delayed Wheelchair Need in MS Patients

   By Donato Paolo Mancini 
 

Roche Holding AG (ROG.EB) said Thursday that it will present new data for its Ocrevus drug that shows how the drug may delay the need for a wheelchair by seven years for people with a type of multiple sclerosis.

Phase 3 data analyses will be presented from June 16 in Lisbon, the company said. The data is from an exploratory analysis of a study on primary progressive multiple sclerosis and shows Ocrevus patients had a 46% reduction in the risk of progressing to a wheelchair compared to the placebo-treated group.

When this is extrapolated, the data indicates the median for multiple sclerosis patients to require a wheelchair is delayed, increasing to 19.2 years for Ocrevus-treated patients compared to 12.1 years for a placebo, the Swiss company said.

Ocrevus is approved in more than 60 countries and has been used to treat 50,000 patients globally. Buoyed by additional approvals, Ocrevus was a key growth driver in the first-quarter, Roche said in April, totaling sales of 479 million Swiss francs ($485 million), CHF443 million of which were in the United States.

 

Write to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com

 

(END) Dow Jones Newswires

June 14, 2018 01:41 ET (05:41 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.